Measurement properties of the Rajka–Langeland severity score in children and adults with atopic dermatitis
Summary Background Multiple atopic dermatitis (AD) severity scales exist, with no gold standard for use in clinical practice. Objectives To determine the measurement properties of the Rajka–Langeland score and compare it with other clinician‐reported outcomes in adults and children with AD. Methods...
Gespeichert in:
| Veröffentlicht in: | British journal of dermatology (1951) 2021-01, Vol.184 (1), p.87-95 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 95 |
|---|---|
| container_issue | 1 |
| container_start_page | 87 |
| container_title | British journal of dermatology (1951) |
| container_volume | 184 |
| creator | Silverberg, J.I. Lei, D. Yousaf, M. Janmohamed, S.R. Vakharia, P.P. Chopra, R. Chavda, R. Gabriel, S. Patel, K.R. Singam, V. Kantor, R. Hsu, Derek Y. |
| description | Summary
Background
Multiple atopic dermatitis (AD) severity scales exist, with no gold standard for use in clinical practice.
Objectives
To determine the measurement properties of the Rajka–Langeland score and compare it with other clinician‐reported outcomes in adults and children with AD.
Methods
We performed a prospective dermatology practice‐based study using questionnaires and evaluation by a dermatologist (n = 427).
Results
Rajka–Langeland had good concurrent validity with the Eczema Area and Severity Index (Spearman rho = 0·63), SCORing AD (SCORAD) (rho = 0·61), objective‐SCORAD (rho = 0·52) and body surface area (rho = 0·51); good convergent validity with the numeric rating scale average‐itch (rho = 0·60) and worst‐itch (rho = 0·59), Patient‐Oriented Eczema Measure (rho = 0·57), Dermatology Life Quality Index (rho = 0·53), Patient‐Reported Outcomes Measurement Information System Itch Questionnaire (rho = 0·35–0·55) in adults and/or children; fair discriminant validity for patient‐ and physician‐reported global AD severity; good responsiveness to change of severity of AD and itch; good reliability; internal consistency; with no floor or ceiling effects. Interpretability bands (3, clear/almost clear; 4–5, mild; 6–7, moderate; 8–9, severe) and minimal clinically important difference (1 point) were established.
Conclusions
The Rajka–Langeland score showed good construct validity, reliability, internal consistency and responsiveness in adults and children with AD.
What is already known about this topic?
The Rajka–Langeland score was developed to assess the severity of atopic dermatitis (AD).
Limited results have been demonstrated about its validity, responsiveness and interpretability.
What does this study add?
This study demonstrated that the Rajka–Langeland score has good construct validity, responsiveness, reliability and interpretability in the assessment of AD in adults and children.
The Rajka–Langeland score has sufficient validity, reliability and feasibility to be used as an assessment of AD severity in adults and children in clinical practice and trials.
What are the clinical implications of the work?
Clinicians should consider using Rajka–Langeland scoring to assess AD severity and guide therapeutic decision making in clinical practice.
Linked Comment: Reich. Br J Dermatol 2021; 184:6–7.
Plain language summary available online |
| doi_str_mv | 10.1111/bjd.19159 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2396853391</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2396853391</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3539-d49199cbec45981034deb59d6a884229d2c34def4a8e0ea24e6c6f5fc9401f0b3</originalsourceid><addsrcrecordid>eNp1kctOHDEQRS0ECgPJgh9AlrKBRYOfTXsZngFNFClK1pbbrs546Mdgu0Gz4x_4Q74ET4awQKI2JVUdXdWti9AeJUc013E9d0dUUak20ITyUhaMcr6JJoSQk4Kokm-jnRjnhFBOJPmEtjnjopKSTVD7A0wcA3TQJ7wIwwJC8hDx0OA0A_zLzG_N8-PT1PR_oTW9wxHuIfi0xNEOAbDvsZ351gXo8Wpt3NimiB98mmGThoW32EHoTPLJx89oqzFthC-vfRf9ubz4ffa9mP68uj77Ni0sl1wVTiiqlK3BCqkqSrhwUEvlSlNVgjHlmF2NGmEqIGCYgNKWjWysEoQ2pOa76GCtmw3djRCT7ny00GYDMIxRM67KSnKuaEa_vkPnwxj6fJ1m4qQUSpWUZepwTdkwxBig0YvgOxOWmhK9ikDnCPS_CDK7_6o41h24N_L_zzNwvAYefAvLj5X06c35WvIF4b6RyA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2476499612</pqid></control><display><type>article</type><title>Measurement properties of the Rajka–Langeland severity score in children and adults with atopic dermatitis</title><source>Wiley Online Library Journals Frontfile Complete</source><source>Oxford University Press Journals All Titles (1996-Current)</source><creator>Silverberg, J.I. ; Lei, D. ; Yousaf, M. ; Janmohamed, S.R. ; Vakharia, P.P. ; Chopra, R. ; Chavda, R. ; Gabriel, S. ; Patel, K.R. ; Singam, V. ; Kantor, R. ; Hsu, Derek Y.</creator><creatorcontrib>Silverberg, J.I. ; Lei, D. ; Yousaf, M. ; Janmohamed, S.R. ; Vakharia, P.P. ; Chopra, R. ; Chavda, R. ; Gabriel, S. ; Patel, K.R. ; Singam, V. ; Kantor, R. ; Hsu, Derek Y.</creatorcontrib><description>Summary
Background
Multiple atopic dermatitis (AD) severity scales exist, with no gold standard for use in clinical practice.
Objectives
To determine the measurement properties of the Rajka–Langeland score and compare it with other clinician‐reported outcomes in adults and children with AD.
Methods
We performed a prospective dermatology practice‐based study using questionnaires and evaluation by a dermatologist (n = 427).
Results
Rajka–Langeland had good concurrent validity with the Eczema Area and Severity Index (Spearman rho = 0·63), SCORing AD (SCORAD) (rho = 0·61), objective‐SCORAD (rho = 0·52) and body surface area (rho = 0·51); good convergent validity with the numeric rating scale average‐itch (rho = 0·60) and worst‐itch (rho = 0·59), Patient‐Oriented Eczema Measure (rho = 0·57), Dermatology Life Quality Index (rho = 0·53), Patient‐Reported Outcomes Measurement Information System Itch Questionnaire (rho = 0·35–0·55) in adults and/or children; fair discriminant validity for patient‐ and physician‐reported global AD severity; good responsiveness to change of severity of AD and itch; good reliability; internal consistency; with no floor or ceiling effects. Interpretability bands (3, clear/almost clear; 4–5, mild; 6–7, moderate; 8–9, severe) and minimal clinically important difference (1 point) were established.
Conclusions
The Rajka–Langeland score showed good construct validity, reliability, internal consistency and responsiveness in adults and children with AD.
What is already known about this topic?
The Rajka–Langeland score was developed to assess the severity of atopic dermatitis (AD).
Limited results have been demonstrated about its validity, responsiveness and interpretability.
What does this study add?
This study demonstrated that the Rajka–Langeland score has good construct validity, responsiveness, reliability and interpretability in the assessment of AD in adults and children.
The Rajka–Langeland score has sufficient validity, reliability and feasibility to be used as an assessment of AD severity in adults and children in clinical practice and trials.
What are the clinical implications of the work?
Clinicians should consider using Rajka–Langeland scoring to assess AD severity and guide therapeutic decision making in clinical practice.
Linked Comment: Reich. Br J Dermatol 2021; 184:6–7.
Plain language summary available online</description><identifier>ISSN: 0007-0963</identifier><identifier>EISSN: 1365-2133</identifier><identifier>DOI: 10.1111/bjd.19159</identifier><identifier>PMID: 32348552</identifier><language>eng</language><publisher>England: Oxford University Press</publisher><subject>Atopic dermatitis ; Children ; Dermatitis ; Dermatology ; Eczema ; Quality of life ; Validity</subject><ispartof>British journal of dermatology (1951), 2021-01, Vol.184 (1), p.87-95</ispartof><rights>2020 British Association of Dermatologists</rights><rights>2020 British Association of Dermatologists.</rights><rights>Copyright © 2021 British Association of Dermatologists</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3539-d49199cbec45981034deb59d6a884229d2c34def4a8e0ea24e6c6f5fc9401f0b3</citedby><cites>FETCH-LOGICAL-c3539-d49199cbec45981034deb59d6a884229d2c34def4a8e0ea24e6c6f5fc9401f0b3</cites><orcidid>0000-0003-3686-7805 ; 0000-0002-8700-480X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fbjd.19159$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fbjd.19159$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1416,27923,27924,45573,45574</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32348552$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Silverberg, J.I.</creatorcontrib><creatorcontrib>Lei, D.</creatorcontrib><creatorcontrib>Yousaf, M.</creatorcontrib><creatorcontrib>Janmohamed, S.R.</creatorcontrib><creatorcontrib>Vakharia, P.P.</creatorcontrib><creatorcontrib>Chopra, R.</creatorcontrib><creatorcontrib>Chavda, R.</creatorcontrib><creatorcontrib>Gabriel, S.</creatorcontrib><creatorcontrib>Patel, K.R.</creatorcontrib><creatorcontrib>Singam, V.</creatorcontrib><creatorcontrib>Kantor, R.</creatorcontrib><creatorcontrib>Hsu, Derek Y.</creatorcontrib><title>Measurement properties of the Rajka–Langeland severity score in children and adults with atopic dermatitis</title><title>British journal of dermatology (1951)</title><addtitle>Br J Dermatol</addtitle><description>Summary
Background
Multiple atopic dermatitis (AD) severity scales exist, with no gold standard for use in clinical practice.
Objectives
To determine the measurement properties of the Rajka–Langeland score and compare it with other clinician‐reported outcomes in adults and children with AD.
Methods
We performed a prospective dermatology practice‐based study using questionnaires and evaluation by a dermatologist (n = 427).
Results
Rajka–Langeland had good concurrent validity with the Eczema Area and Severity Index (Spearman rho = 0·63), SCORing AD (SCORAD) (rho = 0·61), objective‐SCORAD (rho = 0·52) and body surface area (rho = 0·51); good convergent validity with the numeric rating scale average‐itch (rho = 0·60) and worst‐itch (rho = 0·59), Patient‐Oriented Eczema Measure (rho = 0·57), Dermatology Life Quality Index (rho = 0·53), Patient‐Reported Outcomes Measurement Information System Itch Questionnaire (rho = 0·35–0·55) in adults and/or children; fair discriminant validity for patient‐ and physician‐reported global AD severity; good responsiveness to change of severity of AD and itch; good reliability; internal consistency; with no floor or ceiling effects. Interpretability bands (3, clear/almost clear; 4–5, mild; 6–7, moderate; 8–9, severe) and minimal clinically important difference (1 point) were established.
Conclusions
The Rajka–Langeland score showed good construct validity, reliability, internal consistency and responsiveness in adults and children with AD.
What is already known about this topic?
The Rajka–Langeland score was developed to assess the severity of atopic dermatitis (AD).
Limited results have been demonstrated about its validity, responsiveness and interpretability.
What does this study add?
This study demonstrated that the Rajka–Langeland score has good construct validity, responsiveness, reliability and interpretability in the assessment of AD in adults and children.
The Rajka–Langeland score has sufficient validity, reliability and feasibility to be used as an assessment of AD severity in adults and children in clinical practice and trials.
What are the clinical implications of the work?
Clinicians should consider using Rajka–Langeland scoring to assess AD severity and guide therapeutic decision making in clinical practice.
Linked Comment: Reich. Br J Dermatol 2021; 184:6–7.
Plain language summary available online</description><subject>Atopic dermatitis</subject><subject>Children</subject><subject>Dermatitis</subject><subject>Dermatology</subject><subject>Eczema</subject><subject>Quality of life</subject><subject>Validity</subject><issn>0007-0963</issn><issn>1365-2133</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp1kctOHDEQRS0ECgPJgh9AlrKBRYOfTXsZngFNFClK1pbbrs546Mdgu0Gz4x_4Q74ET4awQKI2JVUdXdWti9AeJUc013E9d0dUUak20ITyUhaMcr6JJoSQk4Kokm-jnRjnhFBOJPmEtjnjopKSTVD7A0wcA3TQJ7wIwwJC8hDx0OA0A_zLzG_N8-PT1PR_oTW9wxHuIfi0xNEOAbDvsZ351gXo8Wpt3NimiB98mmGThoW32EHoTPLJx89oqzFthC-vfRf9ubz4ffa9mP68uj77Ni0sl1wVTiiqlK3BCqkqSrhwUEvlSlNVgjHlmF2NGmEqIGCYgNKWjWysEoQ2pOa76GCtmw3djRCT7ny00GYDMIxRM67KSnKuaEa_vkPnwxj6fJ1m4qQUSpWUZepwTdkwxBig0YvgOxOWmhK9ikDnCPS_CDK7_6o41h24N_L_zzNwvAYefAvLj5X06c35WvIF4b6RyA</recordid><startdate>202101</startdate><enddate>202101</enddate><creator>Silverberg, J.I.</creator><creator>Lei, D.</creator><creator>Yousaf, M.</creator><creator>Janmohamed, S.R.</creator><creator>Vakharia, P.P.</creator><creator>Chopra, R.</creator><creator>Chavda, R.</creator><creator>Gabriel, S.</creator><creator>Patel, K.R.</creator><creator>Singam, V.</creator><creator>Kantor, R.</creator><creator>Hsu, Derek Y.</creator><general>Oxford University Press</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-3686-7805</orcidid><orcidid>https://orcid.org/0000-0002-8700-480X</orcidid></search><sort><creationdate>202101</creationdate><title>Measurement properties of the Rajka–Langeland severity score in children and adults with atopic dermatitis</title><author>Silverberg, J.I. ; Lei, D. ; Yousaf, M. ; Janmohamed, S.R. ; Vakharia, P.P. ; Chopra, R. ; Chavda, R. ; Gabriel, S. ; Patel, K.R. ; Singam, V. ; Kantor, R. ; Hsu, Derek Y.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3539-d49199cbec45981034deb59d6a884229d2c34def4a8e0ea24e6c6f5fc9401f0b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Atopic dermatitis</topic><topic>Children</topic><topic>Dermatitis</topic><topic>Dermatology</topic><topic>Eczema</topic><topic>Quality of life</topic><topic>Validity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Silverberg, J.I.</creatorcontrib><creatorcontrib>Lei, D.</creatorcontrib><creatorcontrib>Yousaf, M.</creatorcontrib><creatorcontrib>Janmohamed, S.R.</creatorcontrib><creatorcontrib>Vakharia, P.P.</creatorcontrib><creatorcontrib>Chopra, R.</creatorcontrib><creatorcontrib>Chavda, R.</creatorcontrib><creatorcontrib>Gabriel, S.</creatorcontrib><creatorcontrib>Patel, K.R.</creatorcontrib><creatorcontrib>Singam, V.</creatorcontrib><creatorcontrib>Kantor, R.</creatorcontrib><creatorcontrib>Hsu, Derek Y.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>British journal of dermatology (1951)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Silverberg, J.I.</au><au>Lei, D.</au><au>Yousaf, M.</au><au>Janmohamed, S.R.</au><au>Vakharia, P.P.</au><au>Chopra, R.</au><au>Chavda, R.</au><au>Gabriel, S.</au><au>Patel, K.R.</au><au>Singam, V.</au><au>Kantor, R.</au><au>Hsu, Derek Y.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Measurement properties of the Rajka–Langeland severity score in children and adults with atopic dermatitis</atitle><jtitle>British journal of dermatology (1951)</jtitle><addtitle>Br J Dermatol</addtitle><date>2021-01</date><risdate>2021</risdate><volume>184</volume><issue>1</issue><spage>87</spage><epage>95</epage><pages>87-95</pages><issn>0007-0963</issn><eissn>1365-2133</eissn><abstract>Summary
Background
Multiple atopic dermatitis (AD) severity scales exist, with no gold standard for use in clinical practice.
Objectives
To determine the measurement properties of the Rajka–Langeland score and compare it with other clinician‐reported outcomes in adults and children with AD.
Methods
We performed a prospective dermatology practice‐based study using questionnaires and evaluation by a dermatologist (n = 427).
Results
Rajka–Langeland had good concurrent validity with the Eczema Area and Severity Index (Spearman rho = 0·63), SCORing AD (SCORAD) (rho = 0·61), objective‐SCORAD (rho = 0·52) and body surface area (rho = 0·51); good convergent validity with the numeric rating scale average‐itch (rho = 0·60) and worst‐itch (rho = 0·59), Patient‐Oriented Eczema Measure (rho = 0·57), Dermatology Life Quality Index (rho = 0·53), Patient‐Reported Outcomes Measurement Information System Itch Questionnaire (rho = 0·35–0·55) in adults and/or children; fair discriminant validity for patient‐ and physician‐reported global AD severity; good responsiveness to change of severity of AD and itch; good reliability; internal consistency; with no floor or ceiling effects. Interpretability bands (3, clear/almost clear; 4–5, mild; 6–7, moderate; 8–9, severe) and minimal clinically important difference (1 point) were established.
Conclusions
The Rajka–Langeland score showed good construct validity, reliability, internal consistency and responsiveness in adults and children with AD.
What is already known about this topic?
The Rajka–Langeland score was developed to assess the severity of atopic dermatitis (AD).
Limited results have been demonstrated about its validity, responsiveness and interpretability.
What does this study add?
This study demonstrated that the Rajka–Langeland score has good construct validity, responsiveness, reliability and interpretability in the assessment of AD in adults and children.
The Rajka–Langeland score has sufficient validity, reliability and feasibility to be used as an assessment of AD severity in adults and children in clinical practice and trials.
What are the clinical implications of the work?
Clinicians should consider using Rajka–Langeland scoring to assess AD severity and guide therapeutic decision making in clinical practice.
Linked Comment: Reich. Br J Dermatol 2021; 184:6–7.
Plain language summary available online</abstract><cop>England</cop><pub>Oxford University Press</pub><pmid>32348552</pmid><doi>10.1111/bjd.19159</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0003-3686-7805</orcidid><orcidid>https://orcid.org/0000-0002-8700-480X</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-0963 |
| ispartof | British journal of dermatology (1951), 2021-01, Vol.184 (1), p.87-95 |
| issn | 0007-0963 1365-2133 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2396853391 |
| source | Wiley Online Library Journals Frontfile Complete; Oxford University Press Journals All Titles (1996-Current) |
| subjects | Atopic dermatitis Children Dermatitis Dermatology Eczema Quality of life Validity |
| title | Measurement properties of the Rajka–Langeland severity score in children and adults with atopic dermatitis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T23%3A00%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Measurement%20properties%20of%20the%20Rajka%E2%80%93Langeland%20severity%20score%20in%20children%20and%20adults%20with%20atopic%20dermatitis&rft.jtitle=British%20journal%20of%20dermatology%20(1951)&rft.au=Silverberg,%20J.I.&rft.date=2021-01&rft.volume=184&rft.issue=1&rft.spage=87&rft.epage=95&rft.pages=87-95&rft.issn=0007-0963&rft.eissn=1365-2133&rft_id=info:doi/10.1111/bjd.19159&rft_dat=%3Cproquest_cross%3E2396853391%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2476499612&rft_id=info:pmid/32348552&rfr_iscdi=true |